Synairgen PLC Sustainability Reports
Synairgen Limited is a respiratory drug discovery and development company focused on severe viral lung infections. Its primary drug candidate is SNG001, an inhaled formulation of interferon beta targeted at broad-spectrum antiviral defense in the lungs.
Sector: Manufacturing
Country: United Kingdom
Exchange: OTC Markets
LEI: 213800IMMTOPPDF8HD24
FIGI: BBG001SMK906
18 reports from 2006 to 2024